Literaturverzeichnis_pd_dr_m_braun

PUBLIKATIONSVERZEICHNIS - Veröffentlichungen in Fachzeitschriften ORGINALARBEITEN 1. M. Schel ing, J. Gnirs, M. Braun, R. Busch, S.Maurer , W.Kuhn, K.Th.M. Schneider, H. Graeff: Optimized differential diagnosis of breast lesions by combined B-mode and color Doppler sonography. Ultrasound Obstet. Gynecol. 10 (1997): 48-53 2. M. Schel ing, M. Braun, Kuhn W, G. Bogner, R. Gruber, J. Gnirs, K.Th.M. Schneider, K. Ulm, S. Rutke, A. Staudach: Combined Transvaginal B-Mode and Color Doppler Sonography for Differential Diagnosis of Ovarian Tumors: Results of a Multivariate Logistic Regression Analysis. Gynecol Oncol. 2000 Apr;77(1):78-86 3. A. Prechtl, N. Harbeck, C. Thomssen, C. Meisner, M. Braun, M. Untch, M. Wieland, B. Lisboa, T. Cufer, H. Graeff, K. Selbmann, M. Schmitt, F. Janicke: Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer. Int J Biol Markers. 2000 Jan-Mar;15(1):73-8. 4. M. Braun, M. Schel ing, W. Kuhn, K. Ulm, S. Rutke, H. Graeff: Combination of B-mode and color Doppler sonography for differential diagnoses of breast lesions. Geburtsh Frauenheilk 2001; 61: 2-6 5. O. Zivanovic, M. Braun, T.-W. Park, W. Kuhn: The impact of the pathologist on the treatment of epithelial ovarial cancer. Verh Dtsch Ges Pathol. 2005; 89:101-10 6. M. Braun, B. Schlehe, A. Faridi, U. Heinrichs, C. Rudlowski: Treatment with Combinations of the Anti-HER2 Antibody Trastuzumab and Capecitabine in Advanced Metastatic Breast Cancer Patients – a Pilot Study. Breast Care 2007;2:227-233 7. C. K. Kuhl, W. Kuhn, M. Braun, H.Schild: Pre-operative staging of breast cancer with breast MRI: One step forward, two steps back? The Breast 2007 Oct 22 Volume 16, Issue 2, Supplement 1, 2007: 34-44 8. J.J. Hernando, T.-W. Park, H.P. Fischer, O. Zivanovic, M. Braun, M. Pölcher, U. Grunn, C. Leutner, B. Pötsch, W. Kuhn: Vaccination with dendritic cel s transfected with mRNA- encoded folate-receptoralpha for relapsed metastatic ovarian cancer. Lancet Oncology 2007 May; 8(5):451-454. 9. K. Yeghiazaryan, S. Mamlouk, D. Trog, H. Moenkemann, M. Braun, W. Kuhn, H. Schild, O. Golubnitschaja: Irradiated breast cancer patients demonstrate subgroup specific regularities in protein expression patterns of circulating leukocytes. Cancer Genomics & Proteomics 2007 (4): 411-418 10. M. Braun, U. Flucke, M. Debald, G. Walgenbach-Bruenagel, K. J. Walgenbach, T. Höller, M. Pölcher, M. Wolfgarten, A. Sauerwald, M. Keyver-Paik, M. Kühr, R. Büttner, W. Kuhn: Detection of lymphovascular invasion in early breast cancer by D2-40 (podoplanin): a clinical y useful predictor for axillary lymph node metastases. Breast Cancer Res Treat (2008) 112:503–511 11. M. Wollenschein, M.M. Montag, K. van der Ven, M. Braun, A. Rohde: Cancer female patients with desire to have children: Significance of cryopreservation of the ovary tissues an example of Cryobank Bonn. Geburtsh Frauenheilk 2008; 68: 188-189 12. M. Braun, M. Pölcher, S. Schrading, O. Zivanovic, Th. Kowalski, U. Flucke, C. Leutner, T.-W. Park - Simon, C. Rudlowski, W. Kuhn, C. K. Kuhl: Influence of preoperative MRI on the surgical management of patients with operable breast cancer. Breast Cancer Res. Treat 2008 Sep;111(1):179-87 13. M. Wollenschein, K. van der Ven, M. Montag, M. Braun, A. Rohde Fertilitätsprotektion bei onkologischen Patientinnen: Kryobank Bonn – Beratung, Anwendung und die Bedeutung für die betroffene Frau. Geburtsh Frauenheilk 2008; 68: 262–267 14. C. Kuhl. C., M. Braun: Magnetic resonance imaging in preoperative staging for breast cancer: pros and contras. Radiologe 2008 Apr;48(4):358-66 15. M. Braun, V. R. Jacobs, S. Wagenpfeil, D. Sattler, R. Bernard, W. Kuhn and A. Ihbe- Heffinger: Cost-Cost Analysis Comparing an Anthracycline/Docetaxel Regime to CMF in Patients with Early Stage Breast Cancer. Onkologie 2009; 32:473-481 16. M. Braun, M. Fountoulakis, I. Seidel, T. Höller, K. Yeghiazaryan, H. Schild, W. Kuhn and O. Golubnitschaja: Down-regulation of microfilamental network-associated proteins in leukocytes of breast cancer patients: potential application to predictive diagnosis. Cancer Genomics and Proteomics 2009; 6:31-40 17. M. Pölcher, S. Mahner, O. Ortmann , J. Hilfrich, M. Braun, W. Kuhn: Neoadjuvant Chemotherapy With Carboplatin and Docetaxel in Advanced Ovarian Cancer – a Prospective Multicenter Phase 2 Trial (PRIMOVAR). Oncol Rep. 2009 Sep;22(3):605-13. 18. M. Debald, M. Pölcher, U. Flucke, G. Walgenbach-Bruenagel, K.J. Walgenbach, T. Höller, M. Wolfgarten, C. Rudlowski, R. Büttner, H. Schild, W. Kuhn, M. Braun: Increased detection of lymphatic vessel invasion by D2-40 (podoplanin) in early breast cancer: possible influence on patient selection for Accelerated Partial Breast Irradiation (APBI). Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1128-33. 19. Flucke U, Flucke MT, Hoy L, Breuer E, Goebbels R, Rhiem K, Schmutzler R, Winzenried H, Braun M, Steiner S, Buettner R, Gevensleben H. Distinguishing medul ary carcinoma of the breast from highgrade hormone receptor-negative invasive ductal carcinoma: an immunohistochemical approach. Histopathology. 2010 Jun;56(7):852-9. 20. Braun M, E. Wardelmann, M. Debald, G. Walgenbach-Brunagel, T. Höller, M. Wolfgarten, A. Sauerwald, C. Rudlowski, R. Büttner, W. Kuhn, M. Pölcher Detection of lymphovascular invasion in vulvar cancer by D2-40 (podoplanin) as a predictor for inguinal lymph node metastases Onkologie. 2009 Dec;32(12):732-8. 21. Pölcher M., Friedrichs N., Rudlowski C. , Fimmers R., Keyver-Paik M.D., Kübler K., Sauerwald A., Büttner R., Kuhn W., Braun M. Changes in Ki-67 Labelling Indices During Neoadjuvant Chemotherapy for Advanced Ovarian Cancer are Associated With Survival. Int J Gynecol Cancer. 2010 May;20(4):555-60. 22. Pölcher M, Braun M, Friedrichs N, Rudlowski C, Bercht E, Fimmers R, Sauerwald A, Keyver-Paik MD, Kübler K, Büttner R, Kuhn WC, Hernando JJ. Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma. Cancer Immunol Immunother. 2010 Jun;59(6):909-19 23. Pölcher M, Rudlowski C, Friedrichs N, Mielich M, Höl er T, Wolfgarten M, Kübler K, Büttner R, Kuhn W, Braun M In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer. Cancer Immunol Immunother. 2010 Jun;59(6):909-19. Epub 2010 Jan 20. BMC Cancer. 2010 Apr 13;10:137. 24. Schrading S, Simon B, Braun M, Wardelmann E, Schild HH, Kuhl CK. MRI-guided breast biopsy: influence of choice of vacuum biopsy system on the mode of biopsy of MRI-only suspicious breast lesions. AJR Am J Roentgenol. 2010 Jun;194(6):1650-7. 25. Pölcher M, Rudlowski C, Friedrichs N, Mielich M, Höl er T, Wolfgarten M, Kübler K, Büttner R, Kuhn W, Braun M. Impact of the menstrual cycle on circulating cel -free DNA. Anticancer Res. 2010 Jun;30(6):2235-40 26. Debald M., Walgenbach-Brünagel G., Braun M. Non-invasive Proteomics - thinking about personalized breast cancer screening and treatment. The EPMA Journal 2010 1;3:413-420 27. Mallmann M., Staratschek-Jox A., Rudlowski C., Braun M., Kuhn W., Schultze J. Prediction and Prognosis: Impact of Gene Expression Profiling in Personalized Treatment of Breast Cancer Patients The EPMA Journal 2010 1;3:413-420 28. Walgenbach KJ, Kuhl C, Rudlowski C, Poelcher M, Sauerwald A, Walgenbach-Brünagel G, Kuhn W, Braun M. A Rare Complication Following Breast Implant Surgery: Capsular Contracture with a Cutaneous Silicone Fistula after Breast Reconstruction with Silicone Gel Implants. Breast Care (Basel). 2011;6(1):51-53 29. Yeghiazaryan K, Cebioglu M, Braun M, Kuhn W, Schild HH, Golubnitschaja O: Noninvasive subcel ular imaging in breast cancer risk assessment: construction of diagnostic windows. Personalized Med 2011, Vol. 8(3):321–330 30. Simons S, Ringsdorf S, Braun M, Mey UJ, Schwindt PF, Ko YD, Schmidt-Wolf I, Kuhn W, Jaehde U. Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care Support Care Cancer. 2011 Jul;19(7):1009-18 31. Debald M, Franken S, Heukamp LC, Linke A, Wolfgarten M, Walgenbach KJ, Braun M, Rudlowski C, Gieselmann V, Kuhn W, Hartmann G, Walgenbach-Brünagel G. Identification of specific nuclear structural protein alterations in human breast cancer. J Cell Biochem. 2011 Nov;112(11):3176-84 32. Kühr M, Wolfgarten M, Stölzle M, Leutner C, Höl er T, Schrading S, Kuhl C, Schild H, Kuhn W, Braun M. Potential Impact of Preoperative Magnetic Resonance Imaging of the Breast on Patient Selection for Accelerated Partial Breast Irradiation. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e541-6 33. Liekweg A, Westfeld M, Braun M, Zivanovic O, Schink T, Kuhn W, Jaehde U. Pharmaceutical care for patients with breast and ovarian cancer Support Care Cancer. 2012 Nov;20(11):2669-77 IF:2,56 34. Stoetzer OJ, Fersching DM, Salat C, Steinkohl O, Gabka CJ, Hamann U, Braun M, Fel er AM, Heinemann V, Siegele B, Nagel D, Holdenrieder S. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol. 2013 Feb;34(1):81-90 35. Weber SK, Sauerwald A, Pölcher M, Braun M, Debald M, Serce NB, Kuhn W, Brunagel-Walgenbach G, Rudlowski C. Detection of lymphovascular invasion by d2-40 (podoplanin) immunoexpression in endometrial cancer. Int J Gynecol Cancer. 2012 Oct;22(8):1442-8 36. Debald M, Kaiser C, Abramian A, Schildhaus HU, Locher P, Wolfgarten M, Kuhn W, Braun M. Evaluation of e-cadherin, ki-67 and lymphatic vessel invasion in abdominal metastases of human breast cancer Anticancer Res. 2013 May;33(5):1971-5 37. Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M, Kuhn W, Schild HH. Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J. 2013 Feb 19;4(1) 38. Stoetzer OJ, Fersching DM, Salat C, Steinkohl O, Gabka CJ, Hamann U, Braun M, Feller AM, Heinemann V, Siegele B, Nagel D, Holdenrieder S.Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin. Cancer Lett. 2013 Apr 21. pii: S0304-3835(13)00347-9

Source: http://www.gynonko.de/aerzte/pdf/literaturverzeichnis_pd_dr_m_braun.pdf

Microsoft word - nurse_screener_pds_092809.doc

Participant Screener – Nurse PDS OVERVIEW frog design is looking to speak with qualified nurses with experience in providing education and instruction to Rheumatoid Arthritis (RA) patients on the self-administration of biologic RA drug treatments. All interviews would be conducted in a facility in Los Angeles. Method  3 nurses -must have done auto-injection training with patien

Copyright © 2010-2014 Drug Shortages pdf